PPARγ mutations, lipodystrophy and diabetes.

Area of Science:

• Endocrinology and genetics of nuclear receptors.

Background:

• Partial familial lipodystrophy type 3 (FPLD3) is linked to mutations in the peroxisome proliferator-activated receptor gamma (PPARγ) nuclear receptor.
• PPARγ plays a critical role in adipogenesis, glucose homeostasis, and lipid metabolism.

Purpose of the Study:

• To review the fundamental biology of PPARγ.
• To examine PPARγ mutations causing FPLD3 and their clinical manifestations.
• To survey non-pathogenic PPARγ variants associated with type 2 diabetes.

Main Methods:

• Literature review of PPARγ biology.
• Analysis of genetic variants in PPARγ associated with lipodystrophy and type 2 diabetes.

Main Results:

• Specific PPARγ mutations lead to FPLD3 by disrupting normal receptor function.
• Non-pathogenic PPARγ variants are associated with metabolic syndromes like type 2 diabetes, highlighting the receptor's broad regulatory roles.

Conclusions:

• PPARγ is a key regulator in metabolic health, with mutations leading to distinct clinical syndromes.
• Understanding PPARγ variants is crucial for diagnosing and managing lipodystrophy and type 2 diabetes.